Drugs / OT-A201
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05828459 | Jul 2023 → Jan 2027 expected | cancer, hematopoietic and lymphoid cell neoplasm | Onward Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OT-A201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05828459 ↗ |
| Route | Intravenous | “OT-A201 administered by IV infusion” NCT05828459 ↗ |